EPHA2 and hepatocellular carcinoma: For specific molecular targets in different digestive system tumors, clinical trials targeting the colorectal cancer stem cell marker LGR5 (NCT05759728) in colorectal cancer, EphA2 (NCT05003895) in pancreatic cancer, GPC3 (NCT02395250, NCT03146234), and EpCAM (NCT02729493) in hepatocellular carcinoma, as well as trials targeting MUC1 in pancreatic cancer (NCT03267173) and intrahepatic cholangiocarcinoma (NCT02587689), are all underway, offering broader prospects for the diversified development of CAR-T cell therapy.